Zevra Therapeutics

US · ZVRA #3562 by market cap

10.98 -0.10 -0.90%

Live - 5344 symbols - heartbeat 191s ago · 2026-10-08 10:10

Pre-market 11.06 -0.18%

After-hours 11.19 +0.99%

Market cap: 652.03M
P/E (TTM): 11.81
P/B: 3.00
EPS: 1.35
Div yield: 0.00%
52W pos: 42%

Reader sentiment Are you bullish or bearish on ZVRA?

Anonymous reader poll. Unscientific, not investment advice.

About Zevra Therapeutics

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Founded: 2006
CEO: Mr. Neil F. McFarlane, M.S.
Employees: 61
Headquarters: Boston, Florida, United States of America
Fiscal year end: 12-31
Website: zevra.com

Company profile

Exchange: US
Symbol: ZVRA
Market-cap rank: #3562
Market cap: 652.03M
Float cap: 591.85M
Shares out: 59.38M
Float shares: 53.90M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 10:10:21 · For reference only, not investment advice and not tailored to your situation.